Anders Gustavsson
Overview
Explore the profile of Anders Gustavsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Bauer A, Wittenberg R, Ly A, Gustavsson A, Bexelius C, Tochel C, et al.
Int J Technol Assess Health Care
. 2020 Aug;
:1-7.
PMID: 32847642
Objectives: Due to the nature of Alzheimer's disease (AD), health technology assessment (HTA) agencies might face considerable challenges in choosing appropriate outcomes and outcome measures for drugs that treat the...
22.
Shrestha S, Olen O, Eriksson C, Everhov A, Myrelid P, Visuri I, et al.
Scand J Gastroenterol
. 2020 May;
55(4):430-435.
PMID: 32370571
Whether data on International Classification of Diseases (ICD)-codes from the Swedish National Patient Register (NPR) correctly correspond to subtypes of inflammatory bowel disease (IBD) and phenotypes of the Montreal classification...
23.
Janssen O, Vos S, Garcia-Negredo G, Tochel C, Gustavsson A, Smith M, et al.
Alzheimers Dement
. 2020 Mar;
16(3):461-471.
PMID: 32157788
Introduction: The ROADMAP project aimed to provide an integrated overview of European real-world data on Alzheimer's disease (AD) across the disease spectrum. Methods: Metadata were identified from data sources in...
24.
Green C, Handels R, Gustavsson A, Wimo A, Winblad B, Skoldunger A, et al.
Alzheimers Dement
. 2019 Aug;
15(10):1309-1321.
PMID: 31402324
Introduction: We develop a framework to model disease progression across Alzheimer's disease (AD) and to assess the cost-effectiveness of future disease-modifying therapies (DMTs) for people with mild cognitive impairment (MCI)...
25.
Rudberg A, Berge E, Gustavsson A, Nasman P, Lundstrom E
Eur Stroke J
. 2019 Apr;
3(2):157-164.
PMID: 31008347
Introduction: Information about the impact of functional outcome after stroke is currently missing on health-related quality of life, survival and costs. This information would be valuable for health economic evaluations...
26.
Tochel C, Smith M, Baldwin H, Gustavsson A, Ly A, Bexelius C, et al.
Alzheimers Dement (Amst)
. 2019 Mar;
11:231-247.
PMID: 30906845
Introduction: Clinical trials involving patients with Alzheimer's disease (AD) continue to try to identify disease-modifying treatments. Although trials are designed to meet regulatory and registration requirements, many do not measure...
27.
Wimo A, Jonsson L, Fratiglioni L, Sandman P, Gustavsson A, Skoldunger A, et al.
Alzheimers Res Ther
. 2017 Mar;
9(1):12.
PMID: 28241856
No abstract available.
28.
Gustavsson A, Green C, Jones R, Forstl H, Simsek D, de Reydet de Vulpillieres F, et al.
Alzheimers Dement
. 2017 Jan;
13(3):312-321.
PMID: 28063281
Available data and models for the health-economic evaluation of treatment in Alzheimer's disease (AD) have limitations causing uncertainty to decision makers. Forthcoming treatment strategies in preclinical or early AD warrant...
29.
Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, Van Assche G, et al.
Inflamm Bowel Dis
. 2016 Dec;
23(1):133-142.
PMID: 28002130
Background: Endoscopic balloon dilation (EBD) is widely used to manage Crohn's disease-associated strictures. However, most studies of the safety and efficacy are small and heterogenous. We performed a combined analysis...
30.
Wimo A, Jonsson L, Fratiglioni L, Sandman P, Gustavsson A, Skoldunger A, et al.
Alzheimers Res Ther
. 2016 Dec;
8(1):59.
PMID: 27986093
Background: In this study, we sought to estimate the societal cost of illness in dementia in Sweden in 2012 using different costing approaches to highlight methodological issues. Methods: We conducted...